Literature DB >> 10534730

Emergence and genetic evolution of HIV-1 variants with mutations conferring resistance to multiple reverse transcriptase and protease inhibitors.

M Cabana1, B Clotet, M A Martínez.   

Abstract

The emergence of genotypic resistance in protease and reverse transcriptase (RT) gene regions was longitudinally evaluated in plasma samples from a group of 12 HIV-1-infected patients treated with different combination of antiretroviral therapies and selected on the basis of their clinical failure. Complex mutational patterns in the reverse transcriptase gene were observed. In particular, combinations of AZT (41L, 67N, 70R, 210W, and 219Q/E) and 3TC (184M) were seen in 10 patients. Two patients presented codon 151 multinucleoside analogue resistance (MNR). Additionally, seven patients harbored RT nonnucleoside analogue-related resistance substitutions (98G, 103N, and 181C). Multiple protease-selected mutations were found in each patient with an average of six substitutions per patient, with 10I/F/V, 63P, 71V, 82A/T, 84V, and 90M being the most prevalent substitutions. Overall, these results showed that for most patients virological failure was coupled with detectable genotypic resistance. Furthermore, most patients exhibited genotypic resistance to almost all available anti-HIV-1 drugs. The high viral loads found in most patients at the end of the study suggest that the replication of these multidrug resistant viruses are not severely compromised. Phylogenetic analysis of these pol sequences revealed that a specific HIV-1 genotype prone to develop multidrug resistance was not found. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10534730     DOI: 10.1002/(sici)1096-9071(199912)59:4<480::aid-jmv10>3.0.co;2-8

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  5 in total

1.  A bacteriophage lambda-based genetic screen for characterization of the activity and phenotype of the human immunodeficiency virus type 1 protease.

Authors:  M A Martínez; M Cabana; M Parera; A Gutierrez; J A Esté; B Clotet
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

2.  Role of the human immunodeficiency virus type 1 envelope gene in viral fitness.

Authors:  Hector R Rangel; Jan Weber; Bikram Chakraborty; Arantxa Gutierrez; Michael L Marotta; Muneer Mirza; Patti Kiser; Miguel A Martinez; Jose A Este; Miguel E Quiñones-Mateu
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

3.  Endoribonuclease-prepared short interfering RNAs induce effective and specific inhibition of human immunodeficiency virus type 1 replication.

Authors:  Mireia Gimenez-Barcons; Bonaventura Clotet; Miguel Angel Martinez
Journal:  J Virol       Date:  2007-07-25       Impact factor: 5.103

4.  Trends in prevalence of HIV-1 drug resistance in Thailand 2009-2010.

Authors:  Sayompoo Sanguansittianant; Nattakarn Nooroon; Poonlaph Phaengchomduan; Palanee Ammaranond
Journal:  J Clin Lab Anal       Date:  2013-09       Impact factor: 2.352

Review 5.  The remarkable frequency of human immunodeficiency virus type 1 genetic recombination.

Authors:  Adewunmi Onafuwa-Nuga; Alice Telesnitsky
Journal:  Microbiol Mol Biol Rev       Date:  2009-09       Impact factor: 11.056

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.